ClinicalTrials.gg

Program

QL1203

A development code. Also written as “QL1203 + mFOLFOX6” and “QLC1101+QL1203”.

Its studies are mostly in Colorectal Neoplasms, led by Qilu Pharmaceutical.

Furthest: phase 3, since Jan 14, 20204 company-led studies, 3 open or runningNext primary completion: Feb 28, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical43 open or runningphase 3since Jan 14, 2020Jan 14, 2020Feb 28, 2028phase 1 · NCT07829588

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 14, 2020First study: phase 3 study in Colorectal NeoplasmsFirst studyNCT04233151 · 590 planned · China
  2. Jan 16, 2020Phase 1 study in Healthy MalesNCT04234594 · 94 enrolled · China
  3. Apr 22, 2025Phase 2 study in Solid TumorNCT06949761 · 240 planned
  4. Sep 9, 2026Phase 1 study in RAS Wild-type Metastatic Colorectal CancerNCT07829588 · 136 planned

Ahead

  1. Feb 28, 2028Primary completion: phase 1 study in RAS Wild-type Metastatic Colorectal CancerNCT07829588

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07829588RAS Wild-type Metastatic Colorectal Cancer1Not yet recruitingFeb 28, 2028136
NCT06949761Solid Tumor2Not yet recruitingSep 2026240
NCT04234594Healthy Males · China1UNKNOWNSep 30, 202094
NCT04233151Colorectal Neoplasms · China3RecruitingDec 31, 2024590

How it is read

Names in the registry

  • “QL1203”, 2 entries
  • “QL1203 + mFOLFOX6”, 1 entry
  • “QLC1101+QL1203”, 1 entry

Codes read as this program: QL1203.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
QL1203 (Qilu Pharmaceutical): development program | ClinicalTrials.gg